Compound Profiles
CJC-1295 with DAC
Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation..
Hexarelin
Examorelin | Synthetic Growth Hormone Secretagogue
Hexarelin binds to the growth hormone secretagogue receptor 1a (GHS-R1a) in the brain and pituitary gland. This binding initiates a signaling cascade that stimulates somatotroph cells in the anterior pituitary to produce and release growth hormone.
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take CJC-1295 with DAC with Hexarelin?
Yes, but with caution. Both CJC-1295 with DAC and Hexarelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.
Is CJC-1295 with DAC and Hexarelin safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting. Monitor accordingly.
What are the interactions between CJC-1295 with DAC and Hexarelin?
Both CJC-1295 with DAC and Hexarelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.
How should I time CJC-1295 with DAC and Hexarelin?
CJC-1295 with DAC has a half-life of 6-8 days and Hexarelin has a half-life of 1-2 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.